TABLE 2.
Univariable and multivariable analyses for OS.
| Characteristics | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | p | Hazard ratio (95% CI) | p | |
| Treatment | ||||
| PCT alone | Reference | Reference | ||
| PCT + LRRT | 0.62 (0.37–1.06) | 0.079 | 0.62 (0.36–1.07) | 0.085 |
| PCT + LRRT + bRT | 0.37 (0.20–0.65) | 0.001 | 0.4 (0.22–0.74) | 0.003 |
| Age (years) | ||||
| ≤ 45 | Reference | Reference | ||
| > 45 | 1.64 (1.04–2.59) | 0.034 | 1.66 (1.03–2.66) | 0.036 |
| Sex | ||||
| Male | Reference | |||
| Female | 0.67 (0.36–1.23) | 0.194 | ||
| T stage | ||||
| 1–2 | Reference | |||
| 3–4 | 1.68 (0.86–3.26) | 0.127 | ||
| N stage | ||||
| 0–1 | Reference | Reference | ||
| 2–3 | 2.5 (1.28–4.88) | 0.007 | 2.2 (1.11–4.36) | 0.024 |
| EBV DNA level (copies/mL) | ||||
| < 10,000 | Reference | Reference | ||
| ≥ 10,000 | 2.87 (1.73–4.76) | < 0.001 | 2.34 (1.38–3.95) | 0.002 |
| ALP (U/L) | ||||
| < 110 | Reference | |||
| ≥ 110 | 1.67 (0.88–3.16) | 0.116 | ||
| LDH (U/L) | ||||
| < 250 | Reference | Reference | ||
| ≥ 250 | 2.7 (1.62–4.49) | < 0.001 | 1.97 (1.14–3.42) | 0.016 |
| No. of metastatic lesions | ||||
| 1–3 | Reference | Reference | ||
| 4–5 | 1.75 (1.01–3.02) | 0.046 | 1.31 (0.74–2.32) | 0.361 |
| Property | ||||
| Osteogenesis | Reference | |||
| Osteolysis | 1.3 (0.84–2.02) | 0.240 | ||
| PCT regimen | ||||
| TPF | Reference | |||
| TP | 1.29 (0.69–2.4) | 0.420 | ||
| PF | 1.36 (0.77–2.42) | 0.293 | ||
| GP | 0.9 (0.27–3.05) | 0.872 | ||
| Multiple or other regimes | 1.73 (0.81–3.7) | 0.158 | ||
| Response after PCT | ||||
| PR | Reference | |||
| PD/SD | 1.3 (0.81–2.07) | 0.278 | ||
| Administration of CCT | ||||
| No | Reference | |||
| Yes | 0.98 (0.63–1.53) | 0.941 | ||
Note: All analyses were conducted using the Cox regression model.